Analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Larimar Therapeutics in a research report ...
1 Day LRMR 2.30% DJIA 0.89% Russell 2K 1.03% Health Care/Life Sciences 2.54% ...
Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available ...
Large investors have recently bought and sold shares of the stock. Quarry LP grew its stake in shares of Larimar Therapeutics by 966.7% in the 2nd quarter. Quarry LP now owns 8,000 shares of the ...
Indeed, Larimar Therapeutics (NASDAQ:LRMR) stock is up 170% in the last year, providing strong gains for shareholders. Nonetheless, only a fool would ignore the risk that a loss making company ...
Oppenheimer sets Larimar Therapeutics' price target at $26, anticipating $1.2 billion in global revenues by 2030. The company aims for FDA marketing application submission in late 2025 ...
Shares of Larimar Therapeutics (NASDAQ:LRMR) gained on Wednesday after Oppenheimer launched the company with an Outperform recommendation, citing the potential of its lead asset, nomlabofusp ...
Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics LRMR and Theravance Biopharma TBPH. Industry: Small ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback